Sysmex (OTCMKTS:SSMXY) Downgraded to Hold Rating by Citigroup

Sysmex (OTCMKTS:SSMXY) was downgraded by investment analysts at Citigroup from a “strong-buy” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Sysmex Stock Performance

Shares of SSMXY opened at $8.61 on Monday. The business’s 50 day moving average is $9.33 and its two-hundred day moving average is $10.45. Sysmex has a 52-week low of $8.15 and a 52-week high of $19.65. The firm has a market cap of $5.42 billion, a price-to-earnings ratio of 17.94 and a beta of 1.14. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, February 12th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $837.32 million during the quarter, compared to analysts’ expectations of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. Analysts forecast that Sysmex will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.